
Liquidia Corporation LQDA
€ 42.23
12.4%
Land |
|
IPO-Jahr |
2018 |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ CAPITAL |
Anteile |
86.1 M |
Marktkapitalisierung |
$ 4.08 B |
EBITDA (LTM) |
$ -49.8 M |
P/E (LTM) |
-85.825 |
P/S (LTM) |
37.321993 |
EPS (LTM) |
-0.8 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 5.12 | -1.45 % | $ 43.6 M | Nasdaq Global Select Market | ||
|
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | ||
|
Taysha Gene Therapies
TSHA
|
$ 4.34 | 5.99 % | $ 1.39 B | Nasdaq Global Select Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.56 | -2.77 % | $ 6.2 M | Nasdaq Capital Market | ||
|
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Annovis Bio
ANVS
|
$ 1.2 | 9.63 % | $ 24.7 M | NYSE American | ||
|
United Therapeutics Corporation
UTHR
|
$ 608.19 | 1.14 % | $ 26.9 B | Nasdaq Global Select Market,SPB | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Vericel Corporation
VCEL
|
$ 45.83 | 11.54 % | $ 2.31 B | Nasdaq Global Select Market,SPB | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Veracyte
VCYT
|
$ 52.31 | 4.02 % | $ 4.11 B | Nasdaq Global Market,SPB | ||
|
Exelixis
EXEL
|
$ 72.73 | 0.58 % | $ 19.8 B | Nasdaq Global Select Market,SPB | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Vir Biotechnology
VIR
|
$ 11.67 | 4.01 % | $ 1.62 B | Nasdaq Global Select Market,SPB | ||
|
Viking Therapeutics
VKTX
|
$ 27.96 | 7.17 % | $ 3.15 B | Nasdaq Capital Market | ||
|
Vanda Pharmaceuticals
VNDA
|
$ 3.87 | 3.07 % | $ 228 M | Nasdaq Global Select Market,SPB | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
Verrica Pharmaceuticals
VRCA
|
$ 3.45 | 4.86 % | $ 36.8 M | Nasdaq Global Market | ||
|
Viridian Therapeutics
VRDN
|
$ 29.04 | 15.47 % | $ 2.96 B | Nasdaq Capital Market | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 549.04 | 3.44 % | $ 140 B | Nasdaq Global Select Market,SPB | ||
|
vTv Therapeutics
VTVT
|
$ 23.99 | 1.87 % | $ 94.9 M | Nasdaq Global Select Market | ||
|
Voyager Therapeutics
VYGR
|
$ 1.88 | 2.46 % | $ 110 M | Nasdaq Global Select Market | ||
|
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | ||
|
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | ||
|
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | ||
|
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market | ||
|
Xenetic Biosciences
XBIO
|
$ 2.03 | -2.64 % | $ 3.45 M | Nasdaq Capital Market | ||
|
Xeris Pharmaceuticals
XERS
|
$ 10.48 | 1.21 % | $ 1.68 B | Nasdaq Global Select Market | ||
|
Fennec Pharmaceuticals
FENC
|
$ 10.35 | -3.27 % | $ 296 M | Nasdaq Capital Market | ||
|
X4 Pharmaceuticals
XFOR
|
$ 3.23 | 1.74 % | $ 137 M | Nasdaq Capital Market | ||
|
Xencor
XNCR
|
$ 34.95 | 14.07 % | $ 2.59 B | Nasdaq Global Select Market,SPB | ||
|
Cocrystal Pharma
COCP
|
$ 1.01 | -5.61 % | $ 11.4 M | Nasdaq Capital Market | ||
|
Atea Pharmaceuticals
AVIR
|
$ 4.46 | 6.83 % | $ 363 M | Nasdaq Global Select Market | ||
|
22nd Century Group
XXII
|
$ 0.04 | -19.46 % | $ 7.36 K | NYSE American | ||
|
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 64.2 | 4.03 % | $ 131 B | NYSE,SPB | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Zai Lab Limited
ZLAB
|
$ 22.67 | 3.23 % | $ 24.8 B | Nasdaq Global Select Market | ||
|
Zentalis Pharmaceuticals
ZNTL
|
$ 1.76 | -1.4 % | $ 126 M | Nasdaq Global Market | ||
|
Zoetis
ZTS
|
$ 88.16 | 6.23 % | $ 39.1 B | NYSE,SPB | ||
|
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | ||
|
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market |